- Home
- ARWR vs FDS Comparison
ARWR vs FDS Comparison
Compare ARWR & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | FDS |
|---|---|---|
| Founded | 2003 | 1978 |
| Country | United States | United States |
| Employees | N/A | 6258 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 10.0B |
| IPO Year | 2009 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ARWR | FDS |
|---|---|---|
| Price | $55.13 | $205.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 11 |
| Target Price | $81.50 | ★ $300.10 |
| AVG Volume (30 Days) | ★ 1.9M | 965.1K |
| Earning Date | 05-08-2026 | 03-18-2026 |
| Dividend Yield | N/A | ★ 2.16% |
| EPS Growth | ★ 99.80 | 11.79 |
| EPS | 0.22 | ★ 4.06 |
| Revenue | $16,142,321.00 | ★ $1,435,351,000.00 |
| Revenue This Year | N/A | $6.51 |
| Revenue Next Year | N/A | $5.26 |
| P/E Ratio | $249.84 | ★ $50.19 |
| Revenue Growth | N/A | ★ 6.31 |
| 52 Week Low | $10.66 | $185.00 |
| 52 Week High | $76.76 | $473.33 |
Technical Indicators
Market Signals| Indicator | ARWR | FDS |
|---|---|---|
| Relative Strength Index (RSI) | 30.90 | 40.05 |
| Support Level | $36.34 | $185.00 |
| Resistance Level | $66.37 | $230.03 |
| Average True Range (ATR) | 3.12 | 8.62 |
| MACD | -0.84 | 1.49 |
| Stochastic Oscillator | 8.07 | 41.62 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.